Previously, the TMS system was only indicated for adults with MDD who had failed to achieve satisfactory improvement from prior antidepressant medications. The Horizon 3.0 TMS Therapy System is a ...

This approval marks NeuroStar as the first and only transcranial magnetic stimulation (TMS ... therapy represents a novel approach to treating MDD, particularly in younger patients who may ...

(NASDAQ: STIM) this week announced significant progress in expanding access to its NeuroStar TMS Therapy for patients with major depressive disorder (MDD). BlueCross BlueShield of North Carolina ...

TMS has been researched as a putative treatment for MDD for just over a decade. In all there have now been over 35 controlled clinical trials. Recent meta-analyses of the database of TMS studies ...

The FDA has now cleared the Magstim Horizon 3.0 and Inspire Transcranial Magnetic Stimulation Systems for treating adolescent patients aged 15-21 for MDD, providing a non-invasive, non ...

(MENAFN- GlobeNewsWire - Nasdaq) Adolescent patients ages 15-21 can now receive non-invasive TMS for treatment of major depressive disorder (MDD)* MINNEAPOLIS, March 19, 2025 (GLOBE NEWSWIRE ...

Shelly Lahn, CEO of Neuro Wellness TMS Centers ... adults with MDD who have not responded to antidepressant medications. SAINT ® therapy works by leveraging advanced functional MRI imaging ...